Poxel PXXLF Stock
Poxel Price Chart
Poxel PXXLF Financial and Trading Overview
| Poxel stock price | 0.26 USD |
| Previous Close | 0.26 USD |
| Open | 0.7 USD |
| Bid | 0 USD x 0 |
| Ask | 0 USD x 0 |
| Day's Range | 0.7 - 0.7 USD |
| 52 Week Range | 0.25 - 0.7 USD |
| Volume | 100 USD |
| Avg. Volume | 8 USD |
| Market Cap | 15.88M USD |
| Beta (5Y Monthly) | 1.313 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.3 USD |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | N/A |
PXXLF Valuation Measures
| Enterprise Value | 73.92M USD |
| Trailing P/E | N/A |
| Forward P/E | N/A |
| PEG Ratio (5 yr expected) | N/A |
| Price/Sales (ttm) | 2.0734463 |
| Price/Book (mrq) | N/A |
| Enterprise Value/Revenue | 9.654 |
| Enterprise Value/EBITDA | N/A |
Trading Information
Poxel Stock Price History
| Beta (5Y Monthly) | 1.313 |
| 52-Week Change | 3.99% |
| S&P500 52-Week Change | 27.29% |
| 52 Week High | 0.7 USD |
| 52 Week Low | 0.25 USD |
| 50-Day Moving Average | 0.26 USD |
| 200-Day Moving Average | 0.25 USD |
PXXLF Share Statistics
| Avg. Volume (3 month) | 8 USD |
| Avg. Daily Volume (10-Days) | 0 USD |
| Shares Outstanding | 61.06M |
| Float | N/A |
| Short Ratio | N/A |
| % Held by Insiders | 5.72% |
| % Held by Institutions | 4.99% |
| Shares Short | N/A |
| Short % of Float | N/A |
| Short % of Shares Outstanding | N/A |
Dividends & Splits
| Trailing Annual Dividend Rate | 0 |
| Trailing Annual Dividend Yield | 0% |
| 5 Year Average Dividend Yield | N/A |
| Payout Ratio | 0 |
| Last Split Factor |
Financial Highlights
Fiscal Year
| Fiscal Year Ends | December 31, 2024 |
| Most Recent Quarter (mrq) | June 30, 2025 |
| Next Fiscal Year End | December 31, 2025 |
Profitability
| Profit Margin | -178.45% |
| Operating Margin (ttm) | -89.96% |
| Gross Margin | 52.01% |
| EBITDA Margin | 0% |
Management Effectiveness
| Return on Assets (ttm) | -20.71% |
| Return on Equity (ttm) | N/A |
Income Statement
| Revenue (ttm) | 7.66M USD |
| Revenue Per Share (ttm) | 0.14 USD |
| Quarterly Revenue Growth (yoy) | 87.90% |
| Gross Profit (ttm) | 3.98M USD |
| EBITDA | N/A |
| Net Income Avi to Common (ttm) | -13664000 USD |
| Diluted EPS (ttm) | -0.3 |
| Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
| Total Cash (mrq) | 2.06M USD |
| Total Cash Per Share (mrq) | 0.04 USD |
| Total Debt (mrq) | 62.01M USD |
| Total Debt/Equity (mrq) | N/A |
| Current Ratio (mrq) | 0.258 |
| Book Value Per Share (mrq) | -1.326623 |
Cash Flow Statement
| Operating Cash Flow (ttm) | 816K USD |
| Levered Free Cash Flow (ttm) | -10212250 USD |
Profile of Poxel
| Country | United States |
| State | N/A |
| City | Lyon |
| Address | Immeuble Le Sunway |
| ZIP | 69007 |
| Phone | 33 1 44 71 94 94 |
| Website | https://www.poxelpharma.com |
| Industry | Biotechnology |
| Sector(s) | Healthcare |
| Full Time Employees | 5 |
Poxel S.A., a clinical-stage biopharmaceutical company, develops novel treatments for metabolic pathophysiology, type 2 diabetes, and liver diseases. It also develops treatments for rare metabolic diseases and associated steatohepatitis to metabolic dysfunction. The company's lead product is TWYMEEG (Imeglimin), an oral drug candidate that targets mitochondrial dysfunction and approved for the treatment of type 2 diabetes in Japan. It also develops PXL770, an adenosine monophosphate-activated protein kinase enzyme, which is in a Phase 2a clinical trial that treats chronic metabolic diseases, including diseases that affect the liver, such as non-alcoholic steatohepatitis (NASH); PXL065, an earlier stage programs that is in Phase 2 for the treatment of NASH focusing on chronic and rare metabolic indications. The company has a licensing agreement with Enyo Pharma S.A.S. for the development of farnesoid X receptor that is in Phase 2a study for the treatment of hepatitis B and NASH; and DeuteRx LLC for the development of PXL065, a mitochondrial dysfunction; and Sumitomo Pharma for development and commercialization of Imeglimin. Poxel S.A. was incorporated in 2009 and is headquartered in Lyon, France.
Q&A For Poxel Stock
What is a current PXXLF stock price?
Poxel PXXLF stock price today per share is 0.26 USD.
How to purchase Poxel stock?
You can buy PXXLF shares on the OTC Markets EXMKT exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for Poxel?
The stock symbol or ticker of Poxel is PXXLF.
Which industry does the Poxel company belong to?
The Poxel industry is Biotechnology.
How many shares does Poxel have in circulation?
The max supply of Poxel shares is 61.06M.
What is Poxel Price to Earnings Ratio (PE Ratio)?
Poxel PE Ratio is now.
What was Poxel earnings per share over the trailing 12 months (TTM)?
Poxel EPS is -0.3 USD over the trailing 12 months.
Which sector does the Poxel company belong to?
The Poxel sector is Healthcare.